Mostrar el registro sencillo del ítem
| dc.contributor.author | Santos-García, Diego | |
| dc.contributor.author | Cerdán-Sánchez, María | |
| dc.contributor.author | Yanez-Bana, Rosa | |
| dc.contributor.author | Cabo, Iria | |
| dc.contributor.author | Cimas-Hernando, María-Iciar | |
| dc.date.accessioned | 2026-11-11T09:05:22Z | |
| dc.date.available | 2026-11-11T09:05:22Z | |
| dc.date.issued | 2026-08 | |
| dc.identifier.citation | Santos García D, Cerdán Sánchez M, Yáñez Baña R, Cabo I, Cimas Hernando MI. Improvement in Quality of Life and Non-Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa. Euro J of Neurology. agosto de 2026;33(8):e70731. doi:10.1111/ene.70731 | |
| dc.identifier.issn | 1351-5101 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/29159 | |
| dc.description.abstract | BACKGROUND: CVT-301 (Inbrija) has demonstrated its effectiveness in treating OFF periods in people with Parkinson's disease (PwP). However, its effect on non-motor symptoms (NMS) and quality of life has not been researched yet. Our aim was to analyze the change observed in health-related quality of life (HRQoL) and, as a secondary exploratory analysis, NMS associated with OFF episodes in PwP treated with CVT-301. METHODS: INLEVO-LIFE PD (an open-label study of the effect of INhaled LEVOdopa on quality of LIFE and non-motor symptoms in Parkinson's Disease) is a prospective open-label study conducted in five centers in Spain. The change from baseline (V0) to the end of the observational period (12 ± 2 weeks) (V12w) in the 39-item Parkinson's Disease Quality of Life Questionnaire (PDQ-39) total score was the primary efficacy measure. RESULTS: Forty PD patients (age 62.3 ± 9.2 years; 55% males) were included between March/2024 and November/2025. At 12 weeks, 34 patients were using CVT-301 and completed the follow-up (85%). The PDQ39 total score decreased from 43.6 ± 24.2 at V0 to 31.4 ± 20.6 at V12w (p < 0.0001). A significant decrease was observed in the mean score of 4 domains of the PDQ39. NMS burden was reduced at v12w from the OFF state to 30, 60, and 90 min after using CVT-301 (p < 0.0001). Mean daily OFF time decreased by 1.6 ± 1.9 h (p < 0.0001). Adverse events related to CVT-301 were reported in 35% of the patients. CONCLUSION: HRQoL and NMS associated with OFF episodes improved in PwP after 12 weeks using CVT-301. | |
| dc.language.iso | eng | |
| dc.publisher | WILEY | |
| dc.rights | Atribución/Reconocimiento-NoComercial 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/deed.es | * |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Parkinson Disease/drug therapy/psychology | |
| dc.subject.mesh | Quality of Life | |
| dc.subject.mesh | Levodopa/administration & dosage/pharmacology/therapeutic use | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Antiparkinson Agents/administration & dosage/pharmacology/therapeutic use | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Administration, Inhalation | |
| dc.subject.mesh | Prospective Studies | |
| dc.title | Improvement in Quality of Life and Non-Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 42560077 | |
| dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/10.1111/ene.70731 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1111/ene.70731 | |
| dc.journal.title | European Journal of Neurology | |
| dc.identifier.essn | 1468-1331 |